 |
| Sarcopenia Treatment Market |
Sarcopenia is the degenerative loss of skeletal muscle mass and strength
associated with aging. It is a significant cause of physical frailty and
reduced quality of life in the elderly population. The most common symptoms
include fatigue, weakness, slowed gait and physical impairment. Currently,
there is no approved drug for Sarcopenia
Treatment Market Size by regulatory agencies and the primary treatment
strategies are lifestyle and dietary modifications. Protein supplements
containing essential amino acids like creatine, HMB and vitamins D & B are
commonly recommended to promote muscle synthesis. Some prescription drugs
targeted at conditions like osteoporosis have shown benefits inmaintaining
muscle mass as well.
The Global sarcopenia treatment market is estimated to be valued at US$ 3.47 Bn in 2024 and is expected to exhibit a CAGR of 9.5% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the sarcopenia treatment market are Yokogawa, General
Electric, Rockwell Automation, MAVERICK Technologies, Emerson, Siemens, Rudolph
Technologies, Honeywell International, ABB, Schneider Electric, Aspen
Technology.
Some of the key opportunities in the market include development of novel drugs
for effective treatment, nutritional supplements targeting various genes and
pathways involved in sarcopenia, availability of advanced diagnostic tools to
better identify patients.
The leading players are focused on global expansion through collaboration with
local players, acquisitions and by establishing manufacturing and distribution
facilities across major markets to tap into new growth avenues.
Market Drivers
Rising geriatric population worldwide susceptible to age-related muscle loss is
a major driver as around 5-13% of people aged 60 and over are impacted by
sarcopenia. By 2050, over 16% of the world's population is projected to be aged
65 and above.
Market Restraints
High costs associated with the limited treatment options available and lack of
approved drugs are a major restraint. Underdiagnosis is also a challenge due to
lack of standardized diagnostic criteria and testing. Reimbursement issues in
some regions further limits widespread adoption of treatments.
Segment Analysis
The sarcopenia treatment market is dominated by the protein supplements
segment. This is because protein supplements are the most effective and easily
available treatment option for sarcopenia. Protein supplements help in building
muscles and preventing muscle loss. Whey protein supplements are the most
popular as they digest quickly and are easily absorbed by the body. The demand
for whey protein supplements is high among both men and women aged 60 years and
above who are at a high risk of sarcopenia.
Global Analysis
North America dominates the global sarcopenia treatment market and accounted
for the largest revenue share in 2024. This is attributed to high awareness
regarding sarcopenia and availability of advanced treatment options in the
region. Moreover, adoption of nutritional supplements for sarcopenia prevention
and management is high among the aging population in the US and Canada. Europe
is also a major sarcopenia treatment market. However, Asia Pacific is expected
to grow at the fastest pace during the forecast period. Increasing geriatric
population, improving healthcare infrastructure and rising medical tourism are
fueling the market growth in Asia Pacific countries like China, Japan and
India.
Get
More Insights On Sarcopenia
Treatment Market
Comments
Post a Comment